Dr. Changhong Li received his PhD degree in internal medicine and endocrinology from Beijing Medical University (now Peking University School of Medicine) in 1996. In 1998, he worked as the post-doctoral in diabetes and nutrition at the University of Tours, France. After that, he worked as the postdoctoral at the Institute of Diabetes, Metabolic Diseases and Obesity (IDOM) of the University of Pennsylvania School of Medicine for 3 years. Since 2003, he successively served as the scientist, assistant professor and associate professor in in the Department of Endocrinology, Philadelphia Children's Hospital of the University of Pennsylvania, mainly engaged in the research of basic and translational medicine in the fields of diabetes and islet function and metabolism. In September 2018, Dr. Li returned to China and join the Institute, dedicated to the research of basic drug and clinical translation in the fields of rare diseases related to hypoglycemia, diabetes and islet function. In the same year, he was selected as into the high-level talent entrepreneurship program of Nanjing "Entrepreneurship Nanjing".
Dr. Li has been engaged in the research of diabetes and pancreatic islet function for more than 20 years. He has led or participated in the establishment of most existing animal models of congenital hyperinsulinemia in the world, and explained the onset of several main types of congenital hyperinsulinemia Mechanism, which is in the world's leading position in the basic research field of hyperinsulinemia and diabetes. He has published 67 English articles and books, 13 Chinese articles (the H-index is 32), 4 invention patents, and has been invited to give more than 30 speeches in China and internationally. He is a reviewer of many magazines. The food for diabetes management, which is developed by Dr. Li, has been on the industrial development in US. After returning to China, Dr. Li has received the support on three projects of new drug research and development, including the national major project for innovative new drugs. As the class 1 new drug, the application of clinical trial for one of the compounds has been started.